国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
2期
233-235
,共3页
厄贝沙坦%慢性肾脏病%蛋白尿%大剂量%疗效
阨貝沙坦%慢性腎髒病%蛋白尿%大劑量%療效
액패사탄%만성신장병%단백뇨%대제량%료효
Irbesartan%Chronic kidney disease(CKD)%Proteinuria%Large dose%Curative effect
目的 探讨临床上使用大剂量厄贝沙坦对慢性肾脏病患者蛋白尿的治疗效果.方法 以80例为研究对象,给予150 mg/d厄贝沙坦治疗,疗程4周.24例患者为对照组维持剂量;56例患者为观察组逐渐加大剂量(300-600 mg/d),疗程为12月,对各项指标进行对比.结果 治疗后尿蛋白定量及各项指标均有显著的改变(P＜0.05);大剂量厄贝沙坦治疗有效率为78.5％(P＞0.05).结论 大剂量厄贝沙坦治疗慢性肾脏病患者可以明显的降低蛋白尿,具有很好的耐受性和安全性.
目的 探討臨床上使用大劑量阨貝沙坦對慢性腎髒病患者蛋白尿的治療效果.方法 以80例為研究對象,給予150 mg/d阨貝沙坦治療,療程4週.24例患者為對照組維持劑量;56例患者為觀察組逐漸加大劑量(300-600 mg/d),療程為12月,對各項指標進行對比.結果 治療後尿蛋白定量及各項指標均有顯著的改變(P＜0.05);大劑量阨貝沙坦治療有效率為78.5％(P＞0.05).結論 大劑量阨貝沙坦治療慢性腎髒病患者可以明顯的降低蛋白尿,具有很好的耐受性和安全性.
목적 탐토림상상사용대제량액패사탄대만성신장병환자단백뇨적치료효과.방법 이80례위연구대상,급여150 mg/d액패사탄치료,료정4주.24례환자위대조조유지제량;56례환자위관찰조축점가대제량(300-600 mg/d),료정위12월,대각항지표진행대비.결과 치료후뇨단백정량급각항지표균유현저적개변(P＜0.05);대제량액패사탄치료유효솔위78.5％(P＞0.05).결론 대제량액패사탄치료만성신장병환자가이명현적강저단백뇨,구유흔호적내수성화안전성.
Objective To study the clinical treatment effects of large dose of Irbesartan for chronic kidney disease (CKD) patients with their proteinuria.Methods 80 cases as the research object,were given 150 mg/days Irbesartan treatment for 4 weeks.24 patients as control group was given maintenance dose; 56 patients for the observation group gradually increased dose (300 - 600 mg/days),treatment for 12 months,compared to the various index.Results After treatment,the urine protein quantitative and all the indexes had significant changes (P＜O.05); large dose of Irbesartan treatment effective rate was 78.5o-/o (P＞0.05).Conclusions Large dose of Irbesartan in treatment for CKD patients can obviously reduce albuminuria,has very good tolerability and safety.
